Law360 turned to antitrust partner Alicia Batts for her commentary on the potential impact of a recent probe by the Federal Trade Commission (FTC) on the pharmacy benefit management (PBM) industry.
Batts said the FTC increased its focus on pharmaceuticals and PBMs as a result of President Biden signing an executive order seeking to invigorate competition across the American economy, especially with regard to prescription drugs. “Now that there is a full commission, the pharmaceutical industry should anticipate more FTC scrutiny,” she stated.
